AU2007247121A1 - 18,21-didesoxymacbecin derivatives for the treatment of cancer - Google Patents

18,21-didesoxymacbecin derivatives for the treatment of cancer Download PDF

Info

Publication number
AU2007247121A1
AU2007247121A1 AU2007247121A AU2007247121A AU2007247121A1 AU 2007247121 A1 AU2007247121 A1 AU 2007247121A1 AU 2007247121 A AU2007247121 A AU 2007247121A AU 2007247121 A AU2007247121 A AU 2007247121A AU 2007247121 A1 AU2007247121 A1 AU 2007247121A1
Authority
AU
Australia
Prior art keywords
strain
represent
compound according
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007247121A
Other languages
English (en)
Inventor
Nigel Coates
Sabine Gaisser
Christine Martin
Steven Moss
William Vousden
Ming Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotica Technology Ltd
Original Assignee
Biotica Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0609132.6A external-priority patent/GB0609132D0/en
Priority claimed from GB0616637A external-priority patent/GB0616637D0/en
Priority claimed from GBGB0622341.6A external-priority patent/GB0622341D0/en
Application filed by Biotica Technology Ltd filed Critical Biotica Technology Ltd
Publication of AU2007247121A1 publication Critical patent/AU2007247121A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
AU2007247121A 2006-05-09 2007-05-09 18,21-didesoxymacbecin derivatives for the treatment of cancer Abandoned AU2007247121A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0609132.6 2006-05-09
GBGB0609132.6A GB0609132D0 (en) 2006-05-09 2006-05-09 Novel compounds and methods for their production
GB0616637A GB0616637D0 (en) 2006-08-22 2006-08-22 Novel compounds and methods for their production
GB0616637.5 2006-08-22
GBGB0622341.6A GB0622341D0 (en) 2006-11-09 2006-11-09 Novel compounds and methods for their preparation
GB0622341.6 2006-11-09
PCT/EP2007/054476 WO2007128829A2 (en) 2006-05-09 2007-05-09 18,21-didesoxymacbecin derivatives for the treatment of cancer

Publications (1)

Publication Number Publication Date
AU2007247121A1 true AU2007247121A1 (en) 2007-11-15

Family

ID=38476939

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007247121A Abandoned AU2007247121A1 (en) 2006-05-09 2007-05-09 18,21-didesoxymacbecin derivatives for the treatment of cancer

Country Status (9)

Country Link
US (1) US20090253667A1 (cg-RX-API-DMAC10.html)
EP (1) EP1928837A2 (cg-RX-API-DMAC10.html)
JP (1) JP2009536181A (cg-RX-API-DMAC10.html)
KR (1) KR20090005376A (cg-RX-API-DMAC10.html)
AU (1) AU2007247121A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0711093A2 (cg-RX-API-DMAC10.html)
CA (1) CA2651558A1 (cg-RX-API-DMAC10.html)
MX (1) MX2008014278A (cg-RX-API-DMAC10.html)
WO (1) WO2007128829A2 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0718562A2 (pt) * 2006-11-09 2014-04-08 Biotica Tech Ltd Composto, processo para preparar e para gerar análogo de macbecina, análogo de macbecina, composição farmacêutica, uso do análogo de macbecina, e, cepa engenheirada.
EP2121957A4 (en) 2007-01-26 2010-11-10 Kosan Biosciences Inc MACROLACTAMES OBTAINED BY MODIFIED BIOSYNTHESIS
EP2129662A2 (en) * 2007-03-01 2009-12-09 Biotica Technology Limited C21-deoxy ansamycin derivatives as antitumor agents
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
CN101869138B (zh) * 2010-05-28 2012-05-30 江苏省农业科学院 一种微胶囊发酵剂储存保护液

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241754B2 (en) * 2003-06-13 2007-07-10 Kosan Biosciences, Inc. 2-Desmethyl ansamycin compounds
WO2007074347A1 (en) * 2005-12-24 2007-07-05 Biotica Technology Ltd. 21-deoxymacbecin analogues useful as antitumor agents

Also Published As

Publication number Publication date
CA2651558A1 (en) 2007-11-15
JP2009536181A (ja) 2009-10-08
US20090253667A1 (en) 2009-10-08
KR20090005376A (ko) 2009-01-13
EP1928837A2 (en) 2008-06-11
WO2007128829A3 (en) 2008-01-03
BRPI0711093A2 (pt) 2011-08-23
MX2008014278A (es) 2008-11-26
WO2007128829A2 (en) 2007-11-15

Similar Documents

Publication Publication Date Title
US20090209494A1 (en) 21-deoxymacbecin analogues useful as antitumor agents
US20090253667A1 (en) 18 ,21-Didesoxymacbecin Derivatives for the Treatment of Cancer
US20100068203A1 (en) 17-Oxymacbecin Derivatives and Their Use in the Treatment of Cancer and/or B-Cell Malignancies
US20110160175A1 (en) 18,21-Didesoxymacbecin Derivatives for the Treatment of Cancer
EP1973883B1 (en) Novel compounds and methods for their production
US20090117127A1 (en) Novel Compounds and Methods for Their Production
US20090209507A1 (en) 15-O-Desmethylmacbecin Derivatives and Their Use in the Treatment of Cancer or B-Cell Malignancies
US20110091452A1 (en) 4,5-Dihydromacbecin Derivatives and Their Use in the Treatment of Cancer or B-Cell Malignancies
US20090298804A1 (en) Novel Compounds and Methods for Their Production
US20100210597A1 (en) C21-Deoxy Ansamycin Derivatives as Antitumor Agents
EP2079700A1 (en) 18, 21-didesoxymacbecin derivatives for the treatment of cancer

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period